Potential clinical applications of halichondrins in breast cancer and other neoplasms

Código QR

Potential clinical applications of halichondrins in breast cancer and other neoplasms

Vanesa Ortega1, Javier Cort&eacute;s1,21Department of Oncology, Vall d&rsquo;Hebr&oacute;n University Hospital, Barcelona, Spain; 2Vall d&rsquo;Hebron Institute of Oncology (VHIO), Barcelona, SpainAbstract: Halichondrin B is a large polyether macrolide found in a rare...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ortega V, Cortes J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4c1c4f3606b64965b8607abde028cfec
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Implications for breast cancer dormancy in other areas of medicine
por: Rameshwar P
Publicado: (2012)

Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
por: Saksena R, et al.
Publicado: (2013)

How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
por: Katherine D. Crew, et al.
Publicado: (2017)

Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger K, et al.
Publicado: (2015)

Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
por: Konstantin K. Laktionov, et al.
Publicado: (2021)

Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients
por: Joan How, et al.
Publicado: (2021)

The clinical and molecular significance associated with STING signaling in breast cancer
por: Eileen E. Parkes, et al.
Publicado: (2021)

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
por: Cadoo KA, et al.
Publicado: (2014)

Critical analysis of the potential for microRNA biomarkers in breast cancer management
por: Graveel CR, et al.
Publicado: (2015)

Potential of afatinib in the treatment of patients with HER2-positive breast cancer
por: Geuna E, et al.
Publicado: (2012)

Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic
por: Fenil Shah, et al.
Publicado: (2017)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
por: Criscitiello C, et al.
Publicado: (2018)

Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery
por: Sankha S. Basu, et al.
Publicado: (2021)

The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
por: Anthony Goncalves, et al.
Publicado: (2021)

Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
por: Tamar Zahavi, et al.
Publicado: (2021)

Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
por: Marko Lucijanic, et al.
Publicado: (2021)

Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge
por: Grace G. Bushnell, et al.
Publicado: (2021)

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants
por: Matteo Lambertini, et al.
Publicado: (2021)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno I, et al.
Publicado: (2015)

Second Primary Malignancies in Patients with Pancreatic Neuroendocrine Neoplasms: A Population-Based Study on Occurrence, Risk Factors, and Prognosis
por: Tulan Hu, et al.
Publicado: (2021)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Brock Schroeder, et al.
Publicado: (2017)

Clinical application of a lung cancer organoid (tumoroid) culture system
por: Etsuko Yokota, et al.
Publicado: (2021)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Francesco Schettini, et al.
Publicado: (2021)

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study
por: Tom Walsh, et al.
Publicado: (2021)

Study of Selected Flavonoid Structures and Their Potential Activity as Breast Anticancer Agents
por: Mohammed Hadi Ali Al-Jumaili, et al.
Publicado: (2021)

Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
por: Ciara H. O’Flanagan, et al.
Publicado: (2017)

Identification of genes involved in breast cancer and breast cancer stem cells
por: Apostolou P, et al.
Publicado: (2015)

Dormancy in breast cancer
por: Banys M, et al.
Publicado: (2012)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Daniele Cattaneo, et al.
Publicado: (2021)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Natansh D. Modi, et al.
Publicado: (2021)

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
por: Xavier Pivot, et al.
Publicado: (2017)

A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases
por: Natalie S. Joe, et al.
Publicado: (2021)

The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk
por: Thomas P. Slavin, et al.
Publicado: (2017)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021)

Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer
por: Karama Asleh, et al.
Publicado: (2021)

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011)

The AURORA pilot study for molecular screening of patients with advanced breast cancer–a study of the breast international group
por: Marion Maetens, et al.
Publicado: (2017)

Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation
por: Haojia Li, et al.
Publicado: (2021)

Can population breast screening programs be leveraged to reduce the burden of breast cancer?
por: Nehmat Houssami
Publicado: (2021)

Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients
por: Sasha E. Stanton, et al.
Publicado: (2021)